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Nuclear localization signalGlucocorticoid receptor-interacting protein 1 (GRIP1), a p160 family nuclear receptor co-activator protein, has
three activation domains that recruit at least three secondary co-activators: CBP/p300, co-activator-associated
arginine methyltransferase 1, and coiled-coil co-activator, which exhibits histone acetyltransferase and/or argi-
nine methyltransferase activities. The regulatory mechanisms underlying the co-activation functions of GRIP1,
which associates with promyelocytic leukemia protein (PML) in PML-nuclear bodies, are not well-understood.
This study showed that PML speciﬁcally and dramatically enhanced the C-terminal transactivation activity of
GRIP1 by directly binding to GRIP1 but only when it was sumoylated. Most of the transactivation activity resided
in the N-terminal PML regions that are conserved among isoforms. Three N-terminal sumoylation residues (Lys
65, 160, and 490) exhibited differential roles in the regulation of GRIP1 activity, and the sumoylation of Lys 490
acted as the primary nuclear localization signal of PML. While GRIP1 transactivation was stimulated to a similar
degree by PML (K490R), located in the nucleus, and wild-type PML, PML (K490D) and the C-truncated mutant
PML1–489 both displayed an epinuclear localization and were mostly inactive in stimulating GRIP. Based on
these data, nuclear foci, nuclear localization, and the sumoylation status of Lys 490 were not essential for the
enhancement ofGRIP1 activity by PML, but the charge status of Lys 490was important for subcellular localization
of PML and cross-talk between its N- and C-terminal regions to modulate transcriptional activation. Taken
together, these results provide insight into the regulatory mechanisms of PML that control the functional activ-
ities of GRIP1.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
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rights reserved.SRC-2) is one of three structurally related but genetically distinct p160
nuclear receptor (NR) co-activators [1–4]. Three activation domains
(AD) have been identiﬁed in p160: AD1 in the middle region, AD2 in
the C-terminal region, and AD3 in the N-terminal region, and each AD
can independently activate signal transduction [5–10]. AD1 receives
an activating signal from DNA-bound NRs and recruits CREB binding
protein (CBP)/p300 [3,6,9] to activate the transcription machinery
through its histone acetyltransferase activity. Coactivator-associated
arginine methyltransferase 1, a protein with histone methyltransferase
activity, mainly binds to the C-terminal region of GRIP1 to stimulate the
AD2 transactivation functions [10]. AD3 was recently mapped to the
highly conserved N-terminal basic helix–loop–helix/Per–Arnt–Sim
domain of p160 co-activators and was shown to recruit secondary
co-activators, including coiled-coil co-activator and GRIP1-associated
coactivator 63 [5,7].
The most common form of acute promyelocytic leukemia (APL) is
characterized by the (15,17) (q21;q22) chromosomal translocation,
which leads to the fusion of the gene encoding retinoic acid receptor
alpha (RARα) with that encoding promyelocytic leukemia protein
1800 S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–1810(PML) [11–13]. The fusion product, PML-RARα, interferes with the
normal function of PML and plays an essential role in growth sup-
pression and apoptosis. PML is a tumor suppressor that assembles
into a multiprotein nuclear structure to form the PML-nuclear body
(PML-NB) and the PML oncogenic domain. PML itself is the principal
component of PML-NBs, which have been implicated in the regula-
tion of diverse cellular functions. PML contains a SUMO (small
ubiquitin-like modiﬁer) interacting domain (SIM) in its C-terminal
region which is important for interaction with nearby sumoylated
PML to initiate the nucleation of PML-NBs, as well to promote the
recruitment of other PML-NB components such as death-domain
associated protein (Daxx), p53, SUMO, and Sp100 [14–17]. While
the acetylation of PML by p300 in HeLa cells is potentiated by
trichostatin A (TSA) as part of TSA-mediated apoptosis [18], recent
studies have shown that the sumoylation of PML in PML-NB formation
regulates PML-mediated transcription in threeways, including titration,
post-translational modiﬁcation, and compartmentalization [12,19,20].
The PML protein acts as both a transcriptional co-activator and a
co-repressor [21,22], but the contribution of PML-NB to transcriptional
regulation is not well understood.
The formation of PML-NBs relies primarily on the self-assembly of
the N-terminal RBCC (a RING-ﬁnger, two B-boxes and a predicted
α-helical coiled-coil) domain of PML and its sumoylation status [23].
Most, but not all PML-NB formation requires covalent SUMO modiﬁca-
tion or a SIM for targeting PML bodies, as required for SUMO proteases
to remove SUMO. A SIM forms a non-covalent interactionwith SUMO to
attach to its binding partners, the three lysines K65, K160, and K490 in
PML, and all isoforms of PML can be sumoylated in vivo [24,25]. The
sumoylation of K160 by arsenic trioxide (ATO) subsequently leads to
the recruitment of the 11S proteasome, a process that is essential
for the degradation of PML and PML-RARα proteins [26]. The SUMO
modiﬁcation of PML ﬁnely regulates the dynamics of PML-NB, including
ATO- and ring ﬁnger protein 4-induced PML degradation [27]. The
synergistic therapy of all-trans retinoic acid (atRA) and ATO targets
two distinctmoieties of the oncoprotein PML-RARα, with ATO targeting
PML and atRA targeting RARα. ATO degrades both PML-RARα and
PML, but not RARα in APL cells [11]. atRA was found to degrade the
PML-RARα oncoprotein through a caspase-mediated cleavage pathway
and a proteasome-dependent degradation pathway in a biphasic
manner [28]. Additionally, atRA increases the level of the cell mem-
brane arsenic channel aquaglyceroporin 9, which allows more arsenic
to enter cells [29].
Previous work by Baumann et al. demonstrated that the GRIP1 dis-
tribution in the cell is complex and ranges from a diffuse nucleoplasmic
pattern to the formation of discrete intranuclear foci. Additionally, they
reported that the AD1 region of GRIP1 is associated with the formation
of PML-NBs in HeLa cells [30]. While the mechanisms underlying the
function of the p160 co-activator in NR transcriptional activation are
known, the regulation of p160 by PML is not fully understood. The
unique leukemia gene product MOZ-TIF2 may be involved, as it de-
pletes CBP from PML-NBs and leads to the inhibition of p53 and RARβ
transcriptional activities [31–33]. This paper presents several lines of
evidence demonstrating that PML has functional roles in the regulation
of GRIP1 transactivation and NR co-activation, which are mediated, at
least partly, by the relief of the repression and self-association phenom-
ena within the GRIP1 C-terminal region via subcellular colocalization.
2. Materials and methods
2.1. Plasmids
Plasmid DNAs encoding pCMV.PML (isoform VI), pCMV.PML(ΔS)
and pCMV.PLZF were gifts from Dr. H-M Shih (Academia Sinica, Taipei,
Taiwan, ROC) [14] and the plasmids pCMV.PML (isoform IV) and
pCMX.HA.PML.RARα were gifts from Dr. H-Y Kao (Case Western
Reserve University, USA) [34]. The pSG5.HA (hemagglutinin) vectorsencoding various truncated PML fragments were constructed by
inserting EcoRI–XhoI fragments of the appropriate polymerase chain
reaction (PCR)-ampliﬁed PML isoforms. The pSG5.HA vectors
encoding various PML mutants were made by site-directed muta-
genesis using the Promega Gene Edit kit (Promega, Madison, MI,
USA). The pSG5.HA.RARα vector for human RARα was constructed
by inserting EcoRI–XhoI fragments of appropriate PCR-ampliﬁed
RARα into the pSG5.HA vector. The pSG5.HA vectors encoding various
GRIP1 fragments and Zac1 have been described previously [6,8,35].
Vectors encoding the Gal4DBD (DNA-binding domain) or pM vectors
encoding full-length GRIP1 (amino acids 5–1462), GRIP1 (amino acids
5–1121), GRIP1 (amino acids 563–1121), and the GRIP1 C-terminal
region (amino acids 1122–1462) have been described previously
[6,35]. The pEGFP.C2 vectors encoding various PML and GRIP1 frag-
ments were constructed by inserting EcoRI–XhoI fragments of the
pSG5.HA.PMLs and pSG5.HA.GRIP1s into the EcoRI–SalI sites of the
pEGFP.C2 vector. The reporter construct GK1 (Gal4 DNA responsive
reporter) has been described previously [8].
Bacterial expression vectors for glutathione S-transferase (GST)
fused to various PML fragments were constructed by inserting the
appropriate PCR fragments into the EcoRI–XhoI sites of pGEX–4T1.
2.2. Cell culture, transient transfection assays, and ﬂuorescencemicroscopy
HeLa cells were grown in DMEM supplemented with 10% charcoal/
dextran-treated fetal bovine serum. Transient transfections and lucif-
erase assays were performed in 24-well culture dishes as described
previously [36]. The expression of pEGFP fusion proteins in 24-well
culture dishes was observed 16 h after transfection by a ﬂuorescence
microscope (Model DMURE2, Leica, Germany) and analyzed with
Image-Pro®Plus (Media-cybernetics, USA) [36]. Cells grown on cov-
erslips in 24-well tissue culture dishes were transiently transfected
with pSG5.HA vectors encoding various GRIP1 constructs. Cells
were ﬁxed in 3.7% formaldehyde for 10 min before permeabilization
in PBS containing 0.1% Triton X-100 for 10 min. The antibodies used
for immunocytochemistry were: anti-mouse PML (PG-M3; Santa
Cruz Biotechnology, USA) and anti-rabbit HA-probe (Y-11; Santa
Cruz Biotechnology, USA). The secondary antibodies used for staining
were: Alexa Fluor-488 goat anti-mouse IgG (H + L) and Texas Red-X
goat anti-rabbit IgG (H + L) (Molecular Probes, Invitrogen, USA). Slides
were analyzed by a Leica DMI 6000B Inverted Microscope (Leica
Microsystems GmbH, Germany) and images were analyzed with the
MetaMorph® System (Molecular Devices, USA). Nuclei were stained
with DAPI (4′,6-diamidino-2-phenylindole, Roche, Germany). For lucif-
erase assays, the total DNA for reporter analysis was adjusted to 1 μg by
adding the necessary amount of relative empty vector. The luciferase
activities of the transfected cell extracts are presented in relative light
units (RLU) and expressed as the means and standard deviations of
three transfected cultures.
2.3. Protein-protein interaction assays
For GST pull-down assays, 35S-labeled proteins were produced
with the TNT T7-coupled reticulocyte lysate system (Promega, USA),
and GST fusion proteins were produced in Escherichia coli BL21.
Radioactively labeled GRIP1 proteinswere translated in vitro, incubated
with various immobilized GST-PML fusion proteins, eluted and ana-
lyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) as previously described [9].
2.4. Immunoblot analysis
HeLa cell lysates were prepared in lysis buffer (100 mM Tris–HCl
pH 8.0, 150 mM NaCl, 0.1% SDS, and 1% Triton X-100) at 4 °C.
Transfected cell extracts were separated by SDS-PAGE, transferred
onto a polyvinylidine diﬂuoride membrane (Millipore, USA) and
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3A2, Santa Cruz Biotechnology, USA) and HA (3F10, Hoffmann-La
Roche, Switzerland).
3. Results
3.1. PML speciﬁcally enhances the transactivation activity of GRIP1 by
the association with GRIP1 in nuclear bodies
As GRIP1 and PML colocalize in NBs, this study investigated
whether the transactivation activities of GRIP1 are regulated by PML.
By fusing Gal4DBD to the indicated GRIP1 fragments to monitor the
transactivation activity of GRIP1 in HeLa cells, the highest transactivation
activitywas observedwith the GRIP1 fragment consisting of amino acids
563–1121 (Fig. 1A, left panel), which is consistent with our previous
ﬁndings that the N- and C-terminal regions of GRIP1 negatively
auto-regulate its AD1 activity [6,35]. On the other hand, with the PML
mutant from Lys to Arg at residues 65, 160, and 490 labeled as PMLFig. 1. PML, but not PML (ΔS), enhances the C-terminal transactivation activity of GRIP1. (A) He
together with the GK1 reporter gene (0.25 μg), which encodes luciferase under the control of
pSG5.HA.PML (wt or ΔS) (right panel). The numbers above the columns indicate the luciferas
three experiments (mean ± S.D.; n = 3). (B) Various GRIP1 fragments were translated in vitr
Bound proteins were eluted, separated by SDS-PAGE, and visualized by autoradiography. Fo
used in the binding reaction. (C) HeLa cells were transiently transfected either with 0.5 μg w
DAPI staining. Approximately 10 representative transfected HeLa cells were examined under a(ΔS), wild-type PML, but not PML (ΔS), dramatically enhanced the
transactivation activity of GRIP1 via the GRIP1 C-terminus region corre-
sponding to amino acids 1122–1462 (Fig. 1A, right panel, compare histo-
gram5 to others, closed columns). This region is named the AD2 domain,
as another region showing enhanced PML transactivation activity, amino
acids 563–1121,was previously named theAD1 region byBaumann et al.
[30]. Further GST pulldown analysis showed that both wild-type PML
and PML (ΔS) physically and primarily interacted with the GRIP1
C-terminal AD2 domain (Fig. 1B), and both wild-type PML and PML
(ΔS) can form nuclear bodies with no relevance to the interaction
between PML and GRIP1–AD2 (Fig. 1C). While a control experiment in-
dicated that only over-expressed wild-type PML, not PML (ΔS), assisted
Daxx in the formation of nuclear foci by interacting with Daxx's SIM
(amino acids 732–740; data not shown), these data suggested that
wild-type PML, not PML (ΔS), promoted the formation of PML-NB, con-
sistent with our previous study [37]. Indeed, these results imply that the
sumo-modifying characteristic of PML is the primary determinant of its
ability to enhance the transactivation activity of GRIP1 by PML.La cells were transiently transfectedwith 0.3 μg pMor the indicated pM.GRIP1 fragments,
GAL4 response elements, in the presence of 0.2 μg pSG5.HA empty vector (left panel) or
e activity relative to an index of 1 for the pM vector alone. These data are the average of
o and incubated with the indicated bead-bound GST-PML fusion proteins and GST alone.
r comparison, the left-most lane of each panel shows that 9% of the total protein was
ild-type pEGFP.PML or the ΔS mutant for 16 h. All nuclei exhibit blue ﬂuorescence after
ﬂuorescence microscope.
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foci exist based on whether they localize with PML-NBs, as the
GRIP1 region containing amino acids 1122–1462 is necessary for the
formation of all GRIP1 foci, and the region containing amino acids
1057–1109 is responsible for GRIP1 association with PML-NBs but
may not be required for non-PML-NB associated foci [30]. To dissect
the focus formation domain of GRIP1, we truncated GRIP1 from the
N- and C-termini to narrow down the interacting region and used
the EGFP and HA tagging techniques to avoid the need for speciﬁc
antibodies against various GRIP1 constructs. In this way, we avoided
the issues that Baumann et al. encountered ﬁnding GRIP1/TIF2 anti-
bodies that recognize endogenous GRIP1 or a transiently expressed
protein [30]. The regions required for the formation of various
GRIP1 foci were examined using EGFP-tagged GRIP15–478, a truncated
version of a nuclear form of GRIP1. Fig. 2A shows that nuclear foci
were ﬁrst observed with GRIP1 being extended over residue 1200
(white arrows), suggesting that the N-terminal region was important
for the translocation ability of GRIP1. Fig. 2B conﬁrms that ﬁnding
with signiﬁcant expression of both GRIP1563–1121 and GRIP15–1121
(Fig. 2A) in the cytoplasmic space. The same ﬁgure shows that the
HA-tagged GRIP1 mutant, GRIP1563–1462, had an epinuclear localization
and induced the formation of cytoplasmic GRIP1 foci (Fig. 2B, nuclear
portions (DAPI; blue) and GRIP1s (HA antibody; red)), but the
GRIP11122–1462 fragment,whichwasmostly expressed in the cytoplasm,
was able to form nuclear foci that almost overlapped with endogenous
PML-NBs [Fig. 2B, GRIP1s (HA antibody; red), PML-NBs (PML antibody;
green), GRIP1s and PML-NBs overlaps (HA and PML antibodies; yellow),
and nuclear portions (DAPI; blue)]. Therefore, a different set of GRP1
mutants was used to further examine whether GRIP1 foci colocalize
with endogenous PML-NBs. Fig. 2C shows that no GRIP1 focus was
found for GRIP15–1121, but signiﬁcant GRIP1 foci were observed for
GRIP15–1200 and GRIP15–1430, and some of these GRIP1 foci overlap
with endogenous PML-NBs (yellow spots indicated by white arrows in
the ampliﬁed GRIP11122–1462 image). These data suggest that the
C-terminal region of GRIP1 is required for the formation of cytoplasmic
or nuclear foci, and the localization of the foci may depend, along with
other unknown factors, on whether a nuclear localization signal (NLS)
exists in the N-terminal portion of GRIP1.
3.2. Conserved structures of PML isoforms are involved in the regulation
of GRIP1 activity
Additional experiments were performed to determine which fea-
tures of PML stimulate the transactivation activity of GRIP1, as most
PML isoforms contain identical N-terminal sequences before residue
552. The shortest PML isoform is isoform VI, which is composed of
560 amino acids, with eight extra amino acids extending from residue
552. Compared with the well-studied 663-amino-acid isoform IV,
isoforms IV and VI formed nuclear foci in HeLa cells (Fig. 3A). The
C-terminal extension from residue 552 of PML isoform IV decreased
the stimulation of GRIP1 activity by PML (Fig. 3B, compare histograms
2–5 to histogram 7), and the region of amino acids 553–560 of PML
isoform VI was critical for stimulation (Fig. 3B, compare histograms
6 and 7). While the longest PML isoform I resulted in less enhance-
ment than isoform IV (data not shown), the PML C-terminally trun-
cated at residue 394 and the sumoylated PML mutant PML (ΔS) did
not result in appreciable stimulation (Fig. 3B, compare histograms
8 and 9 to histograms 2–7). In addition, the C-truncated mutant
PML1–394 showed a punctate epinuclear localization, and other PML
constructs exhibited concentrated nuclear punctate foci (Fig. 3D,Fig. 2. GRIP1 forms nuclear and cytoplasmic foci. (A-C) HeLa cells were transfected with (A
HA-tagged GRIP1 fragments; (C) 0.5 μg HA vector or the indicated HA-tagged GRIP1 fragm
anti-mouse PML. The secondary antibodies used for immuno-staining were: Texas Red-X go
exhibit blue ﬂuorescence after DAPI staining. Approximately 100 transfected cells were ex
PML) foci (B and C) were marked by white arrows.nuclear portions labeled by dotted circles) upon nuclear localization
analysis. A Western blotting assay suggested that the expression
levels of these PML constructs were similar and were not the cause
of the differences in their GRIP1 stimulation activity and subcellular
localization (Fig. 3C and E).
3.3. Sumoylation status of lysine residues at 65, 160 and 490 in PML and
GRIP1 activities
In addition to our previous ﬁndings that the wild-type and
sumoylationmutant PMLs (PML and PML (ΔS)) showed similar nuclear
punctate foci (Figs. 1C and 3D) but different activation machineries
(Figs. 1A and 3B), many studies suggest that three sumoylation sites
are required for the formation of PML-NBs [12,16,24]. Therefore, the
individual roles of each of the three sumoylation sites at residues 65,
160, and 490 in the regulation of GRIP1 transactivation activity were
determined. By performing site-directed mutagenesis to change Lys to
Arg (Fig. 4A), lysine residue 160 was found to be more important than
the other two lysine residues in the stimulation of GRIP1 transactivation
activity (Fig. 4B, compare histograms 1–5). A two-site mutant at resi-
dues 160 and 490, PML (K160R/K490R), had the same low stimulatory
effect as the three-site mutant (Fig. 4B, compare histograms 3 and 9),
suggesting that lysine residue 65 does not cooperate with residue 160
to stimulate GRIP1 activity (also see Fig. 4B, compare histograms 4, 5,
and 7). Western blotting analysis showed that one major PML band
(labeled PML), one non-speciﬁc band (labeled e), and at least four
sumoylated PML bands (Fig. 4C, labeled a–d) were present for these
wild-type and mutated PMLs. The images of nuclear punctate foci indi-
cated that the single- or double-site mutants had similar types as the
wild-type PML and PML (ΔS) (Fig. 4D). Further ﬂuorescence analysis
using various pEGFP.PMLmutants and wild-type DeRed.PML suggested
that the PML mutants colocalized with wild-type PML in HeLa cells
(data not shown).
3.4. Involvement of the N- and C-termini of PML in the regulation of
GRIP1 activity
Based on the fact that PML truncated at residue 394 forms
epinuclear foci (Fig. 3D) and that it has a bipartite basic NLS located at
amino acids 474–490 (Fig. 5A, labeled NLS1 and 2), the NLS sequence
may be critical in enabling PML to form nuclear punctates. Thus, the
role of lysine residue 490 of PML was investigated, as it was previously
demonstrated to be important for the nuclear localization and
sumoylation of PML. Using PML vectors truncated at residues 489 and
473, epinuclear punctate foci were observed for these vectors (Fig. 5B,
with nuclear portions labeled by DAPI and dotted circles), and trunca-
tion of PMLat residue 489 led to the loss ofmost of its GRIP1 stimulatory
activity (Fig. 5C, compare histograms 5 and 4, middle and right panels),
suggesting that lysine 490 is important for its coactivation function.
Accordingly, the expression levels of EGFP-fused PML proteins and
pSG5.HA.PMLswere similar in HeLa cells (data not shown), which indi-
cated that the nuclear localization of PML is required for the stimulation
of GRIP1 activity.
Because four functional domains of PML, namely a RING-ﬁnger, two
B-boxes and a predicted α-helical coiled-coil domain characteristic of
the RBCC motif in the N-terminal region, are required for NB formation
and homo- or hetero-dimerization [23], we investigated which domain
of PML is important for its activity. Truncated PMLswithN-truncated B1
(PML167–560) and B2 (PML231–560) retained less than 20% and 0.1% of
GRIP1 stimulatory activity, respectively (Fig. 6A, compare histograms) 0.5 μg pEGFP vector or the EGFP-tagged GRIP1 fragments; (B) 0.5 μg of the indicated
ents. The antibodies used for immunocytochemistry were: anti-rabbit HA-probe and
at anti-rabbit IgG (H + L) and Alexa Fluor-488 goat anti-mouse IgG (H + L). All nuclei
amined under a ﬂuorescence microscope. Punctate foci (A) or overlapped (GRIP1 and
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Fig. 4. Combinatorial effects of sumoylation sites in PML on the stimulation of GRIP1 activity. (A) The diagram illustrates the mutation of lysine into arginine at three PML
sumoylation residues, 65, 160 and 490. (B) HeLa cells were transiently transfected with 0.3 μg pM or pM.GRIP1, together with the GK1 reporter gene (0.25 μg) in the presence
of 0.25 μg pSG5.HA or the indicated pSG5.HA.PML fragments. The numbers above the columns indicate the luciferase activity relative to an index of 1 for the pSG5.HA vector
alone. These data are the averages of three experiments (mean ± S.D.; n = 3). (C) The expression of the indicated pSG5.HA.PML fragments transfected into HeLa cells was examined
by Western blotting analysis. (D) HeLa cells were transiently transfected with 0.5 μg pEGFP vector or the indicated pEGFP.PML fragments for 16 h. All nuclei exhibit blue ﬂuorescence
after DAPI staining. Approximately 10 representative transfected HeLa cells were examined under a ﬂuorescence microscope.
1805S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–18101–5), and oneN- and C-truncatedmutant (PML167–490) retained a punc-
tate nuclear distribution and less than 0.1% of GRIP1 stimulatory activity
(Fig. 6A and B, compare histograms 6 and 7 in 6A),while all N-truncated
PML constructs exhibited nuclear localization without foci formation
(Fig. 6B). The data suggested that nuclear localization or foci formation
is not sufﬁcient for GRIP1 stimulatory activity, which is consistent with
our ﬁnding on the function of PML (ΔS) on GRIP1 enhancement.Fig. 3. Nuclear, but not epinuclear localization of PML enhances the transactivation activity o
cells were transfected with 0.5 μg pEGFP.PML isoforms VI and IV. (B) HeLa cells were tran
(0.25 μg), in the presence of 0.25 μg pSG5.HA or the indicated pSG5.HA.PML fragments. Th
for the pSG5.HA vector alone. These data are the averages of three experiments (mean ±
cells was examined by Western blotting analysis. (D) HeLa cells were transiently transfec
after DAPI staining. Approximately 10 representative transfected HeLa cells were examine
(E) The expression of the indicated pEGFP.PML fragments transfected into HeLa cells was e3.5. Positive charge at lysine 490 and the NLS
To further explore the dual role of lysine residue 490, we examined
the role of sumoylation and nuclear localization by performing
site-directed mutagenesis of Lys to Arg (R), Ala (A), or Asp (D). While
the PML (K490R) mutant retained most of the stimulatory activity
(Fig. 7A, compare histograms 2 and 3), the PML (K490A) and PMLf GRIP1. (A) The diagram depicts the conserved domain of various PML isoforms. HeLa
siently transfected with 0.3 μg pM or pM.GRIP1, together with the GK1 reporter gene
e numbers above the columns indicate the luciferase activity relative to an index of 1
S.D.; n = 3). (C) The expression of the pSG5.HA.PML fragments transfected into HeLa
ted with 0.5 μg of pEGFP.PML fragments for 16 h. All nuclei exhibit blue ﬂuorescence
d under a ﬂuorescence microscope. Nuclear portions were labeled by dotted circles.
xamined by Western blotting analysis.
Fig. 5. Residue 490 is important for GRIP1 stimulatory activity. (A) The diagram illustrates the NLS of PML. (B) HeLa cells were transiently transfected with 0.5 μg of the indicated
pEGFP.PML fragments for 16 h. All nuclei exhibit blue ﬂuorescence after DAPI staining. Approximately 10 representative transfected HeLa cells were examined under a ﬂuorescence
microscope. Nuclear portions were labeled by dotted circles. (C) HeLa cells were transiently transfected with 0.3 μg pM or the indicated pM.GRIP1 fragments, together with the GK1
reporter gene (0.25 μg), in the presence of 0.25 μg pSG5.HA or the indicated pSG5.HA.PML fragments. The numbers above the columns indicate the luciferase activity relative to an
index of 1 for the pSG5.HA vector alone. These data are the average of three experiments (mean ± S.D.; n = 3).
1806 S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–1810(K490D) mutants both lost one veriﬁed sumoylation site and the NLS,
and these losses affected GRIP1 activity. PML (K490D) lacked stimulato-
ry activity but exhibited an epinuclear localization (Fig. 7), whereas
PML (K490A)was half as active as thewild-type andwas partially local-
ized to the nucleus (Fig. 7A, compare histograms 4 and 5; Fig. 7B, with
nuclear portions labeled by dotted circles). Although lysine residue
487 had no function in NLS2 of C-terminal truncated PML (PML1–489),
we investigated its role in the full-length PML. The PML mutants PML
(K487A) and PML (K487R), aswell as PML1–489, all exhibited epinuclear
localization and lost most of their stimulatory activity towards GRIP1
(Fig. 7A, compare histograms 6 and 7 to 2), suggesting that lysine 487
could not be replaced by arginine but lysine residue 490 could. While
the expression of these PMLmutants did not account for these observa-
tions (Fig. 7C), all these data suggested that NLS2 leads to nuclear local-
ization when lysine 490 is positively charged.
4. Discussion
Recent studies have demonstrated that an SIM in PML is not
essential for PML-NB formation in the absence of endogenous PML
bodies [38,39]. PML isoform VI, which does not contain an SIM, wasstill able to form nuclear bodies. As isoform VI is the shortest isoform,
the nuclear dynamics of PML VI and the other isoforms were explored
in the study. The results showed that the extra C-terminal sequence
of the nuclear isoforms except for isoform VI might negatively regu-
late the GRIP1 transactivation activity via the conserved region
(amino acid 552) of all PMLs, suggesting that the regulation may
occur through the interaction with HDAC1 [40]. On the other hand,
the SUMO-deﬁcient PML, PML (ΔS), formed similar nuclear foci as
wild-type PML [39] but failed to stimulate appreciable GRIP1
transactivation activity (Fig. 1). Therefore, the formation of nuclear
foci may not be required for PML stimulatory activity. This is further
supported by the fact that two nuclear N-truncated PMLs, PML106–560
and PML167–560, failed to form foci but were able to stimulate apprecia-
ble transactivation activity (Fig. 6).
The N- and C-truncation strategy demonstrated that residue 490
was involved in nuclear localization, the N-terminal B boxwas required
for the regulation of transcriptional activation, and the cross-talk be-
tween the N- and C-termini determined foci formation (Figs. 5 and 6).
While PML possesses a bipartite basic NLS located at amino acids
474–490, this is the ﬁrst paper to detail the role of Lys residue 490 in
the bipartite basic NLS. The C-truncated PML1–489 demonstrated that
Fig. 6. N-truncated PML localized to the nucleus lacks GRIP1 stimulatory activity. (A) HeLa cells were transiently transfected with 0.3 μg pM or the indicated pM.GRIP1 fragments,
together with the GK1 reporter gene (0.25 μg), in the presence of 0.25 μg pSG5.HA or the indicated pSG5.HA.PML fragments. The numbers above the columns indicate the luciferase
activity relative to an index of 1 for the pSG5.HA vector alone. These data are the averages of three experiments (mean ± S.D.; n = 3). (B) HeLa cells were transiently transfected
with 0.5 μg pEGFP vector or the indicated pEGFP.PML fragments. Approximately 10 representative transfected HeLa cells were examined under a ﬂuorescence microscope.
1807S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–1810residue 490was essential for NLS2 to be functional (Fig. 5), and the two
lysine residues (at 490 and 487) within the NLS2 region exhibited
different tolerances to residue changes. As the positive charge (lysine
or arginine) of residue 490 is important in retaining the nuclear locali-
zation of PML and the enhancement of the GRIR1 transactivation activ-
ity, the charge of the positive residue at 487 (K487R)would result in the
loss of both functions (Fig. 7), resulting in the different roles of these
two lysine residues in the nuclear localization of PML. In addition, the
N-truncated PML231–560 failed to enhance the GRIR1 transactivation
activity (Fig. 6), and the C-truncated PML167–490 induced the formation
of nuclear foci but was unable to enhance GRIR1 transactivation activity
(Fig. 6). Together, these ﬁndings indicated that the maximal enhance-
ment of GRIR1 transactivation activity by PML (i.e., PML167-560) requires
not only the formation of nuclear foci but also cross-talk between its N-
and C-termini.A number of PML-NB components were identiﬁed as regulatory fac-
tors (or candidates) modulating the activities of transcriptional
coregulators [20,41]. Additionally, the stability of PML-NB relies on the
very long residence times of speciﬁc PML isoforms, in particular PML V
and VI [38,39]. Therefore, while the three sumoylation sites in PML pro-
vide considerable ﬂexibility for controlling the residence times of PML at
NBs, our data demonstrated that various combinations of mutations at
the three sumoylation sites could result in different levels of effects on
the GRIP1 stimulatory activity; for example, the double mutant PML
(K160/490R) had the same effect as PML (ΔS) and PML (k65/K160/
490R) (Fig. 4). Accordingly, the transcriptional coactivation of Lys resi-
dues at 65, 160 and 490 was consistent with their roles determined in
previous studies, which also indicated that Lys residue 160 is the pre-
dominant sumoylation site [24–26]. In this work, we provided several
lines of evidence, including the results of the PML C-truncated at residue
Fig. 7. A positive charge at residue 490 is required for PML stimulation of GRIP1 activity. (A) HeLa cells were transiently transfected with 0.3 μg pM or the indicated pM.GRIP1 frag-
ments, together with the GK1 reporter gene (0.25 μg), in the presence of 0.25 μg pSG5.HA or the indicated pSG5.HA.PML fragments. The numbers above the columns indicate the
luciferase activity relative to an index of 1 for the pSG5.HA vector alone. These data are the averages of three experiments (mean ± S.D.; n = 3). (B) HeLa cells were transiently
transfected with 0.5 μg of the indicated pEGFP.PML fragments for 16 h. Approximately 10 representative transfected HeLa cells were examined under a ﬂuorescence microscope.
Nuclear portions were labeled with dotted circles. (C) The expression of the indicated pEGFP.PML fragments transfected into HeLa cells was examined byWestern blotting analysis.
1808 S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–1810489, to demonstrate the role of Lys residue 490 of PML in its nuclear lo-
calization and coactivation. Although pointmutations of Lys residue 490
into Ala, Asp, and Arg did not affect nuclear foci formation, the number
of foci and their enhancement of the transactivation activity were lessthan for the wild-type and K490R PML (Fig. 7). In addition to the cyto-
plasmic localization of K487R, these results nevertheless do not fully
support the functional role of Lys residue 490 (or 487) within NLS2 of
PML. Thus, this issue will be investigated in the future.
1809S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–1810In this work, PML, not RARα, dramatically enhanced the
transactivation activity of GRIP1, which suggests that the
C-terminal region of GRIP1 rather than the nuclear receptor-binding
motif [42] is the major regulatory target within cells. Our previous
proposed working model [35] of protein–protein interactions and the
regulatory roles of the GRIP1 C-terminus also supports our current
ﬁndings. Recent studies demonstrate that GRIP1 is found in PML-NBs
and SRC-1 is actively transported from PML-NBs to the intra-nuclear
ﬁlamentous structure by ligand-activated androgen receptors, implying
that the function of this sub-nuclear structure includes the regulation of
steroid hormone action [30,43]. In this regard, our data showed that
PML further enhances GRIP1-induced NR transcriptional activities,
while PML–RARα suppresses those activities (data not shown). SRC-3
is phosphorylated by p38 MAPK and subsequently degraded by
proteasomes in response to atRA [44,45]. While SRC-1 and GRIP1 (or
SRC-2) can also be phosphorylated in response to several stimuli and
regulated by the ubiquitin–proteasomepathway, they are not degraded
upon atRA activation of RARα, thus suggesting a relatively target-
speciﬁc coactivator effect for atRA.
According to our microscopic data, few GRIP1 foci overlapped with
PML-NBs, suggesting that PML might enhance GRIP1-dependent
transactivation outside of PML-NBs. Consistently, PML is able to
enhance the transactivation activity of both cytoplasmic and nuclear
GRIP1563–1121 (no GRIP1 foci) (Figs. 1A and 2B). In addition, this infer-
ence is in a good agreement with another study regarding physical
and functional interactions between PML and Zac1 (zinc-ﬁnger protein
which regulates apoptosis and cell cycle arrest 1) in HeLa cells [37]. In
this study, the truncation of GRIP1 demonstrated that its N- and
C-terminal regions are important for its nuclear localization and foci for-
mation, respectively, and that both can alter the biochemical properties
of various GRIP1 constructs, such as protein stability and coactivation
[35]. Together, these ﬁndings indicate that GRIP1563–1121 (cytoplasmic
and nuclear localizations) has better transactivation activity than
GRIP15–1121 (nuclear localization) and GRIP1563–1462 (epinuclear foci),
although a great deal of work is needed to link the subcellular localiza-
tion of GRIP1 (or GRIP1 foci) with its coactivation.
A recent study demonstrated that the direct binding of ATO
induces PML oligomerization, which increases the interaction between
PML and Ubc9 and enhances sumoylation and degradation of PML [46].
Our unpublished data are consistent with the notion that ATO
suppressed Ubc9-induced PML-dependent GRIP1 transactivation activ-
ities, but that ATO lost its ability to degrade PML–RARα proteins at
relatively high concentrations, attenuating its suppression of the tran-
scriptional activities. Given that the mode of action of atRA/ATO
has been utilized systematically to establish a model for studying
various cellular transcriptional regulation programs [47], we believe
that cross-talk pathways involving PML, RARα, and components of
PML-NBs may remain to be identiﬁed, and these pathways are
described in detail in this study.
5. Conclusions
Our results provide insight into the regulatory mechanisms of PML
that control the functional activities of GRIP1. The charge status of Lys
490 is important for the subcellular localization of PML, and the
cross-talk between the N- and C-terminal regions is important for
the modulation of transcriptional activation.
Acknowledgements
We thank Dr. H-M Shih (Academia Sinica, Taipei, Taiwan, ROC) and
H-Y Kao (Case Western Reserve University, USA) for expression DNAs.
The authors declare no conﬂict of interest. This work was supported
by grants from the National Science Council [NSC 98-2320-B-016-
012-MY3 to S-M Huang]; National Defense Medical Bureau
[DOD-98-T04-03 to C-L Ho, DOD-100-C02-03 to Y-J Hsu]; Tri-ServiceGeneral Hospital [TSGH-C99-015-S02 to Y-J Hsu, TSGH-C100-054 to
C-L Ho]; and the Teh-Tzer Study Group for Human Medical Research
Foundation [A98-1018 and A100-1032 to C-L Ho], Taiwan, ROC.
References
[1] B. York, B.W. O'Malley, Steroid receptor coactivator (SRC) family:masters of systems
biology, J. Biol. Chem. 285 (2010) 38743–38750.
[2] C. Leo, J.D. Chen, The SRC family of nuclear receptor coactivators, Gene 245 (2000)
1–11.
[3] J.J. Voegel, M.J. Heine, C. Zechel, P. Chambon, H. Gronemeyer, TIF2, a 160 kDa
transcriptional mediator for the ligand-dependent activation function AF-2 of
nuclear receptors, EMBO J. 15 (1996) 3667–3675.
[4] H. Hong, K. Kohli, A. Trivedi, D.L. Johnson, M.R. Stallcup, GRIP1, a novel mouse
protein that serves as a transcriptional coactivator in yeast for the hormone binding
domains of steroid receptors, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4948–4952.
[5] Y.H. Chen, J.H. Kim, M.R. Stallcup, GAC63, a GRIP1-dependent nuclear receptor
coactivator, Mol. Cell. Biol. 25 (2005) 5965–5972.
[6] S.M. Huang, Y.S. Cheng, Analysis of two CBP (cAMP-response-element-binding
protein-binding protein) interacting sites in GRIP1 (glucocorticoid-receptor-
interacting protein), and their importance for the function of GRIP1, Biochem. J.
382 (2004) 111–119.
[7] J.H. Kim, H. Li, M.R. Stallcup, CoCoA, a nuclear receptor coactivator which acts
through an N-terminal activation domain of p160 coactivators, Mol. Cell 12
(2003) 1537–1549.
[8] S.M. Huang, M.R. Stallcup, Mouse Zac1, a transcriptional coactivator and repressor
for nuclear receptors, Mol. Cell. Biol. 20 (2000) 1855–1867.
[9] H. Ma, H. Hong, S.M. Huang, R.A. Irvine, P. Webb, P.J. Kushner, G.A. Coetzee, M.R.
Stallcup, Multiple signal input and output domains of the 160-kilodalton nuclear
receptor coactivator proteins, Mol. Cell. Biol. 19 (1999) 6164–6173.
[10] D. Chen, H. Ma, H. Hong, S.S. Koh, S.M. Huang, B.T. Schurter, D.W. Aswad, M.R.
Stallcup, Regulation of transcription by a protein methyltransferase, Science 284
(1999) 2174–2177.
[11] Z.Y. Wang, Z. Chen, Acute promyelocytic leukemia: from highly fatal to highly
curable, Blood 111 (2008) 2505–2515.
[12] T.H. Shen, H.K. Lin, P.P. Scaglioni, T.M. Yung, P.P. Pandolﬁ, The mechanisms of
PML-nuclear body formation, Mol. Cell 24 (2006) 331–339.
[13] G.G. Maul, D. Negorev, P. Bell, A.M. Ishov, Review: properties and assembly
mechanisms of ND10, PML bodies, or PODs, J. Struct. Biol. 129 (2000) 278–287.
[14] D.Y. Lin, Y.S. Huang, J.C. Jeng, H.Y. Kuo, C.C. Chang, T.T. Chao, C.C. Ho, Y.C. Chen,
T.P. Lin, H.I. Fang, C.C. Hung, C.S. Suen, M.J. Hwang, K.S. Chang, G.G. Maul, H.M.
Shih, Role of SUMO-interacting motif in Daxx SUMO modiﬁcation, subnuclear
localization, and repression of sumoylated transcription factors, Mol. Cell 24
(2006) 341–354.
[15] I. Louria-Hayon, T. Grossman, R.V. Sionov, O. Alsheich, P.P. Pandolﬁ, Y. Haupt, The
promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition
and degradation, J. Biol. Chem. 278 (2003) 33134–33141.
[16] S. Zhong, S. Muller, S. Ronchetti, P.S. Freemont, A. Dejean, P.P. Pandolﬁ, Role of
SUMO-1-modiﬁed PML in nuclear body formation, Blood 95 (2000) 2748–2752.
[17] D. Negorev, A.M. Ishov, G.G. Maul, Evidence for separate ND10-binding and
homo-oligomerization domains of Sp100, J. Cell Sci. 114 (2001) 59–68.
[18] F. Hayakawa, A. Abe, I. Kitabayashi, P.P. Pandolﬁ, T. Naoe, Acetylation of PML is
involved in histone deacetylase inhibitor-mediated apoptosis, J. Biol. Chem. 283
(2008) 24420–24425.
[19] J.L. Best, S. Ganiatsas, S. Agarwal, A. Changou, P. Salomoni, O. Shirihai, P.B. Meluh,
P.P. Pandolﬁ, L.I. Zon, SUMO-1 protease-1 regulates gene transcription through
PML, Mol. Cell 10 (2002) 843–855.
[20] S. Zhong, P. Salomoni, P.P. Pandolﬁ, The transcriptional role of PML and the nuclear
body, Nat. Cell Biol. 2 (2000) E85–E90.
[21] R.D. Everett, S. Rechter, P. Papior, N. Tavalai, T. Stamminger, A. Orr, PML contributes
to a cellularmechanism of repression of herpes simplex virus type 1 infection that is
inactivated by ICP0, J. Virol. 80 (2006) 7995–8005.
[22] D.Y. Lin, M.Z. Lai, D.K. Ann, H.M. Shih, Promyelocytic leukemia protein (PML)
functions as a glucocorticoid receptor co-activator by sequestering Daxx to the
PML oncogenic domains (PODs) to enhance its transactivation potential, J. Biol.
Chem. 278 (2003) 15958–15965.
[23] K. Jensen, C. Shiels, P.S. Freemont, PML protein isoforms and the RBCC/TRIM
motif, Oncogene 20 (2001) 7223–7233.
[24] T. Kamitani, H.P. Nguyen, K. Kito, T. Fukuda-Kamitani, E.T. Yeh, Covalent modiﬁca-
tion of PML by the sentrin family of ubiquitin-like proteins, J. Biol. Chem. 273
(1998) 3117–3120.
[25] T. Kamitani, K. Kito, H.P. Nguyen, H.Wada, T. Fukuda-Kamitani, E.T. Yeh, Identiﬁcation
of three major sentrinization sites in PML, J. Biol. Chem. 273 (1998) 26675–26682.
[26] V. Lallemand-Breitenbach, J. Zhu, F. Puvion, M. Koken, N. Honore, A.
Doubeikovsky, E. Duprez, P.P. Pandolﬁ, E. Puvion, P. Freemont, H. de The, Role
of promyelocytic leukemia (PML) sumoylation in nuclear body formation, 11S
proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor
alpha degradation, J. Exp. Med. 193 (2001) 1361–1371.
[27] V. Lallemand-Breitenbach, M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou,
J. Zhu, B. Raught, H. de The, Arsenic degrades PML or PML-RARalpha through a
SUMO-triggered RNF4/ubiquitin-mediated pathway, Nat. Cell Biol. 10 (2008)
547–555.
[28] C. Nervi, F.F. Ferrara, M. Fanelli, M.R. Rippo, B. Tomassini, P.F. Ferrucci, M.
Ruthardt, V. Gelmetti, C. Gambacorti-Passerini, D. Diverio, F. Grignani, P.G.
Pelicci, R. Testi, Caspases mediate retinoic acid-induced degradation of the
1810 S.-T. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1799–1810acute promyelocytic leukemia PML/RARalpha fusion protein, Blood 92 (1998)
2244–2251.
[29] J. Leung, A. Pang, W.H. Yuen, Y.L. Kwong, E.W. Tse, Relationship of expression of
aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells, Blood
109 (2007) 740–746.
[30] C.T. Baumann, H. Ma, R. Wolford, J.C. Reyes, P. Maruvada, C. Lim, P.M. Yen, M.R.
Stallcup, G.L. Hager, The glucocorticoid receptor interacting protein 1 (GRIP1)
localizes in discrete nuclear foci that associate with ND10 bodies and are enriched
in components of the 26S proteasome, Mol. Endocrinol. 15 (2001) 485–500.
[31] J. Liang, L. Prouty, B.J. Williams, M.A. Dayton, K.L. Blanchard, Acute mixed lineage
leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and
TIF2, Blood 92 (1998) 2118–2122.
[32] K.B. Kindle, P.J. Troke, H.M. Collins, S. Matsuda, D. Bossi, C. Bellodi, E. Kalkhoven, P.
Salomoni, P.G. Pelicci, S. Minucci, D.M. Heery, MOZ-TIF2 inhibits transcription
by nuclear receptors and p53 by impairment of CBP function, Mol. Cell. Biol. 25
(2005) 988–1002.
[33] H.M. Collins, K.B. Kindle, S. Matsuda, C. Ryan, P.J. Troke, E. Kalkhoven, D.M. Heery,
MOZ-TIF2 alters cofactor recruitment and histone modiﬁcation at the RARbeta2
promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent
activators, J. Biol. Chem. 281 (2006) 17124–17133.
[34] E.L. Reineke, M. Lam, Q. Liu, Y. Liu, K.J. Stanya, K.S. Chang, A.R. Means, H.Y. Kao,
Degradation of the tumor suppressor PML by Pin1 contributes to the cancer
phenotype of breast cancer MDA-MB-231 cells, Mol. Cell. Biol. 28 (2008)
997–1006.
[35] P.Y. Liu, T.Y. Hsieh, W.Y. Chou, S.M. Huang, Modulation of glucocorticoid
receptor-interacting protein 1 (GRIP1) transactivation and co-activation activi-
ties through its C-terminal repression and self-association domains, FEBS J. 273
(2006) 2172–2183.
[36] S.M. Huang, S.P. Huang, S.L. Wang, P.Y. Liu, Importin alpha1 is involved in the
nuclear localization of Zac1 and the induction of p21WAF1/CIP1 by Zac1,
Biochem. J. 402 (2007) 359–366.
[37] C.L. Ho, Y.C. Huang, C.K. Tai, S.T. Liu, J.K. Wang, W.M. Wang, S.M. Huang, Modula-
tion of the Zac1's transactivation and coactivation functions via PML and Daxx
within distinct subcellular localizations, Int. J. Biochem. Cell Biol. 42 (2010)
902–910.[38] P. Brand, T. Lenser, P. Hemmerich, Assembly dynamics of PML nuclear bodies in
living cells, PMC Biophys. 3 (2010) 3.
[39] S. Weidtkamp-Peters, T. Lenser, D. Negorev, N. Gerstner, T.G. Hofmann, G.
Schwanitz, C. Hoischen, G. Maul, P. Dittrich, P. Hemmerich, Dynamics of compo-
nent exchange at PML nuclear bodies, J. Cell Sci. 121 (2008) 2731–2743.
[40] W.S. Wu, S. Vallian, E. Seto, W.M. Yang, D. Edmondson, S. Roth, K.S. Chang, The
growth suppressor PML represses transcription by functionally and physically
interacting with histone deacetylases, Mol. Cell. Biol. 21 (2001) 2259–2268.
[41] Y.L. Chang, C.J. Huang, J.Y. Chan, P.Y. Liu, H.P. Chang, S.M. Huang, Regulation of
nuclear receptor and coactivator functions by the carboxyl terminus of
ubiquitin-conjugating enzyme 9, Int. J. Biochem. Cell Biol. 39 (2007) 1035–1046.
[42] M. Bommer, A. Benecke, H. Gronemeyer, C. Rochette-Egly, TIF2 mediates the
synergy between RARalpha 1 activation functions AF-1 and AF-2, J. Biol. Chem.
277 (2002) 37961–37966.
[43] O.J. Rivera, C.S. Song, V.E. Centonze, J.D. Lechleiter, B. Chatterjee, A.K. Roy, Role
of the promyelocytic leukemia body in the dynamic interaction between the
androgen receptor and steroid receptor coactivator-1 in living cells, Mol. Endocrinol.
17 (2003) 128–140.
[44] M. Gianni, E. Parrella, I. Raska Jr., E. Gaillard, E.A. Nigro, C. Gaudon, E. Garattini, C.
Rochette-Egly, P38MAPK-dependent phosphorylation and degradation of
SRC-3/AIB1 and RARalpha-mediated transcription, EMBO J. 25 (2006) 739–751.
[45] S. Kyakumoto, N. Kito, N. Sato, Expression of cAMP response element binding
protein (CREB)-binding protein (CBP) and the implication in retinoic acid-
inducible transcription activation in human salivary gland adenocarcinoma cell
line HSG, Endocr. Res. 29 (2003) 277–289.
[46] X.W. Zhang, X.J. Yan, Z.R. Zhou, F.F. Yang, Z.Y. Wu, H.B. Sun, W.X. Liang, A.X. Song,
V. Lallemand-Breitenbach, M. Jeanne, Q.Y. Zhang, H.Y. Yang, Q.H. Huang, G.B.
Zhou, J.H. Tong, Y. Zhang, J.H. Wu, H.Y. Hu, H. de The, S.J. Chen, Z. Chen, Arsenic
trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding
PML, Science 328 (2010) 240–243.
[47] P.Z. Zheng, K.K. Wang, Q.Y. Zhang, Q.H. Huang, Y.Z. Du, Q.H. Zhang, D.K. Xiao, S.H.
Shen, S. Imbeaud, E. Eveno, C.J. Zhao, Y.L. Chen, H.Y. Fan, S. Waxman, C. Auffray, G.
Jin, S.J. Chen, Z. Chen, J. Zhang, Systems analysis of transcriptome and proteome in
retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic
leukemia, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7653–7658.
